AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
AAPL   318.11 (+0.44%)
MSFT   181.81 (+0.13%)
FB   229.14 (-1.32%)
GOOGL   1,420.28 (-0.08%)
AMZN   2,410.39 (-0.47%)
NVDA   341.01 (-2.21%)
GE   7.29 (+7.21%)
TSLA   820.23 (+0.17%)
AMD   52.74 (-0.85%)
T   31.85 (+3.34%)
ACB   15.30 (-1.99%)
GILD   74.92 (+2.38%)
DIS   121.53 (+0.48%)
Log in

NASDAQ:IOVAIovance Biotherapeutics Stock Price, Forecast & News

$38.09
+0.68 (+1.82 %)
(As of 05/27/2020 04:00 PM ET)
Add
Compare
Today's Range
$34.68
Now: $38.09
$38.32
50-Day Range
$29.06
MA: $34.88
$41.00
52-Week Range
$16.12
Now: $38.09
$41.49
Volume1.78 million shs
Average Volume1.80 million shs
Market Capitalization$4.83 billion
P/E RatioN/A
Dividend YieldN/A
Beta1.2
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. The company's lead product candidate is lifileucel, an adoptive cell therapy that is in Phase II clinical trial using tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors for the treatment of metastatic melanoma. It is also developing LN-145, an autologous adoptive cell therapy to treat cervical and head and neck cancers. The company has research collaboration and clinical grant agreements with Moffitt to evaluate TIL therapy in a clinical trial that combines TIL with nivolumab in NSCLC; strategic alliance agreement with M.D. Anderson Cancer Center to conduct clinical and preclinical research studies; strategic alliance agreement with Roswell Park Cancer Institute to conduct a clinical research study of TIL therapy in bladder cancer; collaboration agreement with MedImmune to conduct clinical and preclinical research in immuno-oncology; preclinical research collaboration with the Ohio State University; and a preclinical research collaboration with Cellectis S.A. to investigate transcription activator-like effector nucleases. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was founded in 2007 and is headquartered in San Carlos, California.
Read More
Iovance Biotherapeutics logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 3.2Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.34 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:IOVA
CUSIPN/A
Phone650-260-7120

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.92 per share

Profitability

Net Income$-197,560,000.00

Miscellaneous

Employees88
Market Cap$4.83 billion
Next Earnings Date8/6/2020 (Estimated)
OptionableOptionable

Receive IOVA News and Ratings via Email

Sign-up to receive the latest news and ratings for IOVA and its competitors with MarketBeat's FREE daily newsletter.

Iovance Biotherapeutics (NASDAQ:IOVA) Frequently Asked Questions

How has Iovance Biotherapeutics' stock been impacted by COVID-19 (Coronavirus)?

Iovance Biotherapeutics' stock was trading at $29.58 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, IOVA shares have increased by 28.8% and is now trading at $38.09. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Iovance Biotherapeutics?

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Iovance Biotherapeutics in the last year. There are currently 15 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Iovance Biotherapeutics.

When is Iovance Biotherapeutics' next earnings date?

Iovance Biotherapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 6th 2020. View our earnings forecast for Iovance Biotherapeutics.

How were Iovance Biotherapeutics' earnings last quarter?

Iovance Biotherapeutics Inc (NASDAQ:IOVA) posted its quarterly earnings data on Tuesday, May, 5th. The biotechnology company reported ($0.55) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.53) by $0.02. View Iovance Biotherapeutics' earnings history.

What price target have analysts set for IOVA?

15 brokerages have issued 1-year target prices for Iovance Biotherapeutics' shares. Their forecasts range from $27.00 to $65.00. On average, they anticipate Iovance Biotherapeutics' stock price to reach $40.71 in the next year. This suggests a possible upside of 6.9% from the stock's current price. View analysts' price targets for Iovance Biotherapeutics.

Has Iovance Biotherapeutics been receiving favorable news coverage?

Media headlines about IOVA stock have trended somewhat positive recently, according to InfoTrie. The research firm identifies negative and positive press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Iovance Biotherapeutics earned a media sentiment score of 1.6 on InfoTrie's scale. They also gave media coverage about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news aboutIovance Biotherapeutics.

Who are some of Iovance Biotherapeutics' key competitors?

What other stocks do shareholders of Iovance Biotherapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iovance Biotherapeutics investors own include Applied Materials (AMAT), Portola Pharmaceuticals (PTLA), Immunomedics (IMMU), Kadmon (KDMN), BlackRock (BLK), CA (CA), Seattle Genetics (SGEN), Bristol-Myers Squibb (BMY), Micron Technology (MU) and NVIDIA (NVDA).

Who are Iovance Biotherapeutics' key executives?

Iovance Biotherapeutics' management team includes the following people:
  • Dr. Maria Fardis, CEO, Pres & Director (Age 51)
  • Mr. Timothy E. Morris, CFO, Principal Accounting Officer, Corp. Sec. & Treasurer (Age 57)
  • Dr. Frederick G. Vogt Ph.D., Esq., Gen. Counsel (Age 45)
  • Mr. Howard B. Johnson, Sr. VP of Corp. Devel., Alliance Management & Program Management (Age 59)
  • Dr. Elma S. Hawkins Ph.D., MBA, Advisor to the Board (Age 62)

What is Iovance Biotherapeutics' stock symbol?

Iovance Biotherapeutics trades on the NASDAQ under the ticker symbol "IOVA."

Who are Iovance Biotherapeutics' major shareholders?

Iovance Biotherapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (9.20%), BlackRock Inc. (7.80%), Franklin Resources Inc. (4.12%), State Street Corp (3.47%), Victory Capital Management Inc. (1.57%) and Victory Capital Management Inc. (1.57%). Company insiders that own Iovance Biotherapeutics stock include Iain D Dukes, Merrill A Mcpeak and Wayne P Rothbaum. View institutional ownership trends for Iovance Biotherapeutics.

Which institutional investors are selling Iovance Biotherapeutics stock?

IOVA stock was sold by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Wellington Management Group LLP, Victory Capital Management Inc., Victory Capital Management Inc., Alliancebernstein L.P., QVT Financial LP, Franklin Resources Inc., and Sumitomo Mitsui Trust Holdings Inc.. View insider buying and selling activity for Iovance Biotherapeutics.

Which institutional investors are buying Iovance Biotherapeutics stock?

IOVA stock was bought by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Rothschild & Co. Asset Management US Inc., Lord Abbett & CO. LLC, Rice Hall James & Associates LLC, Bank of New York Mellon Corp, BlackRock Inc., Prosight Management LP, and Nuveen Asset Management LLC. Company insiders that have bought Iovance Biotherapeutics stock in the last two years include Iain D Dukes, Merrill A Mcpeak, and Wayne P Rothbaum. View insider buying and selling activity for Iovance Biotherapeutics.

How do I buy shares of Iovance Biotherapeutics?

Shares of IOVA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Iovance Biotherapeutics' stock price today?

One share of IOVA stock can currently be purchased for approximately $38.09.

How big of a company is Iovance Biotherapeutics?

Iovance Biotherapeutics has a market capitalization of $4.83 billion. The biotechnology company earns $-197,560,000.00 in net income (profit) each year or ($1.59) on an earnings per share basis. Iovance Biotherapeutics employs 88 workers across the globe.

What is Iovance Biotherapeutics' official website?

The official website for Iovance Biotherapeutics is www.iovance.com.

How can I contact Iovance Biotherapeutics?

Iovance Biotherapeutics' mailing address is 999 SKYWAY ROAD SUITE 150, SAN CARLOS CA, 94070. The biotechnology company can be reached via phone at 650-260-7120 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.